Literature DB >> 9711464

Nociceptin-induced apparent hyperalgesia in mice as a result of the prevention of opioid autoanalgesic mechanisms triggered by the stress of an intracerebroventricular injection.

C Suaudeau1, S Florin, J C Meunier, J Costentin.   

Abstract

The effects on nociperception of nociceptin/Orphanin FQ (noc/OFQ), the endogenous ligand of the ORL1 (opioid receptor like 1) receptor, have been evaluated in mice upon intracerebroventricular injection of 10 to 10,000 ng doses of the peptide. In the hot plate test (55 degrees C) the licking, rearing and jump latencies were significantly reduced by noc/OFQ (100-250 ng). Noc/OFQ (100-1000 ng) also reduced the latency to tail withdrawal in the tail flick test. In the formalin test (injection in a hind paw of a formalin solution), noc/OFQ (100 ng) increased significantly the duration of paw licking and/or biting at the earliest period of observation. In the writhing test, the number of writhes evoked by intraperitoneal administration of dilute acetic acid was not modified by noc/OFQ at doses in the range of 10-1000 ng, but was decreased by 10,000 ng. The reduction in jump latency in the hot plate test was observed even when mice were pretreated with morphine (2 mg/kg, s.c.). The analgesic effect of acetorphan (5 mg/kg, i.v.) was also reduced by nociceptin (100 ng); on the other hand the hyperalgesic effect of naloxone (4.5 mg/kg, s.c.) was not additive with that of nociceptin (100 ng). Comparing in various tests the nociceptive thresholds of uninjected mice to that of saline i.c.v. injected mice, it appeared that the latter injection induced an increase in these thresholds which was prevented by nociceptin. It is suggested that nociceptin displays hyperalgesic effects by preventing autoanalgesic (opioidergic) mechanisms triggered by the stress elicited by intracerebroventricular injection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9711464     DOI: 10.1111/j.1472-8206.1998.tb00966.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  8 in total

1.  Nociceptin/orphanin FQ blocks the antinociception induced by mu, kappa and delta opioid agonists on the cold water tail-flick test.

Authors:  Xiaohong Chen; Ellen B Geller; Martin W Adler
Journal:  Eur J Pharmacol       Date:  2006-11-10       Impact factor: 4.432

2.  Nociceptin produces antinociception after spinal administration in amphibians.

Authors:  Craig W Stevens; Kristin K Martin; Brad W Stahlheber
Journal:  Pharmacol Biochem Behav       Date:  2008-09-05       Impact factor: 3.533

3.  Parsing the hedonic and motivational influences of nociceptin on feeding using licking microstructure analysis in mice.

Authors:  Ian A Mendez; Nigel T Maidment; Niall P Murphy
Journal:  Behav Pharmacol       Date:  2016-09       Impact factor: 2.293

4.  Pharmacological attenuation of chronic alcoholic pancreatitis induced hypersensitivity in rats.

Authors:  Sabrina L McIlwrath; Karin N Westlund
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

5.  Involvement of phospholipid signal transduction pathways in morphine tolerance in mice.

Authors:  F L Smith; A B Lohmann; W L Dewey
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

6.  Blockade of mu-opioid receptors reveals the hyperalgesic effect of orphanin FQ/nociceptin in the rat hot plate test.

Authors:  K Lutfy; N T Maidment
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

7.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

8.  Minocycline enhances the effectiveness of nociceptin/orphanin FQ during neuropathic pain.

Authors:  Katarzyna Popiolek-Barczyk; Ewelina Rojewska; Agnieszka M Jurga; Wioletta Makuch; Ferenz Zador; Anna Borsodi; Anna Piotrowska; Barbara Przewlocka; Joanna Mika
Journal:  Biomed Res Int       Date:  2014-09-03       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.